Annual Report & Accounts for the year ended 30 April 2017

Sustained growth through innovation and diversification

Chairman's Letter

Consort has delivered another year of underlying growth and further enhanced its margins.

Dr Peter Fellner

Read more

Chief Executive's Review

Jonathan Glenn

Consort Medical has again delivered growth and made good progress with its innovation and development pipeline.

Read more

Financial Review

Paul Hayes

Consort has grown EBIT and margins in both divisions and reduced the level of net debt while continuing to invest in the business.

Read more

2017 Highlights

  • Consort Medical has continued to deliver profitable growth on a reported basis with operating leverage yielding an 8.3% increase in EBIT on 6.2% higher sales
  • Underlying Group EBIT, at constant exchange rates, was 4.1% higher on 2.0% of sales growth
Read more

Group at a glance

A leading global CDMO providing advanced delivery technologies, formulation and manufacturing solutions for drugs.

Who are are

  • Leading global CDMO, providing advanced delivery technologies, formulation and manufacturing solutions for drugs
  • Offering customers a single source for drug and device development, formulation, manufacturing and fill/finish, the Group comprises two integrated operating divisions:
Bespak Logo
Bespak Logo
Read more

Downloads

Strategic Report

Our Business

Our Business

Strategic Report

Our Performance

Our Performance

Our Governance

Our Governance

Our Financials

Our Financials